Glyburide |
Sulfonylureas |
Suppressed KATP channels and inhibition of ASC agglomeration |
MCC950 |
Hydrolysis of ATP |
Metformin |
Biguanide |
Activation of AMPK |
Liraglutide |
GLP‐1 analogs |
Inhibition of NLRP3 inflammasome |
Dapagliflozin |
SGLT‐2 inhibitors |
Activation of AMPK |
Empagliflozin |
Ticagrelor |
CY‐09 |
Glitazones |
Inhibition of NLRP3 ATPase activity |
Arsenic trioxide(As2O3) |
Arsenic compounds |
Inhibition of NLRP3 activation and release of IL‐1β |
Edaravone |
Substituted 2‐pyrazolin‐5‐ones |
Inhibition of NLRP3 activation and release of IL‐1β. Reduced caspase-1 and NF-kB expression and ROS scavenging |
Atorvastatin |
Statins |
Inhibition of NLRP3 activation and release of IL‐1β. Reduced caspase-1 and NF-kB expression and ROS scavenging |
Allopurinol |
Xanthine oxidase inhibitor |
Scavenging of ROS and inhibition of uric acid production |
BAY11‐7082 |
Vinyl sulfones |
Inhibition of ATPase |
MNS |
Beta‐Nitrostyrenes |
Alteration of cysteine residue and inhibition of ATPase |
INF39 |
Acrylate derivatives |
Inhibition of ATPase |
EMD638683 |
Acylhydrazone |
Reduced NLRP3 and IL‐1β expression |
FC11A‐2 |
Benzimidazoles |
Inhibition of autocleavage of pro‐caspase‐1 and IL‐1β expression |
Dapansutrile (OLT1177) |
Sulfonyl nitriles |
Inhibitor of NACHT and ATPase |
BOT‐4‐one |
Benzoxathiole derivatives |
Inhibitor of NACHT and ATPase |
Tranilast |
Tryptophan derivative |
Binds with the NACHT and inhibits the interaction of NLRP3–NLRP3 and NLRP3-ASC |
BHB |
Natural products |
Inhibition of outward movement of K+ and reduced agglomeration |
Parthenolide |
Inhibitor of NACHT ATPase and caspase-1 inhibitor |
Oridonin |
Binds irreversibly with Cys27 residue of NLRP3 9 and inhibits the interaction of NLRP3–NEK7 |